| 1 |
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia
Open access |
19 Apr 2012 |
3,934 |
| 2 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker, Michael Albrecht Nauck · The Lancet
|
Nov 2006 |
3,921 |
| 3 |
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care
Open access |
19 Apr 2012 |
3,225 |
| 4 |
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care
Open access |
13 Dec 2014 |
3,098 |
| 5 |
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
Michael Albrecht Nauck, Anders H. Frid, Kjeld Hermansen et al. · Diabetes Care
Open access |
17 Oct 2008 |
1,128 |
| 6 |
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
Michael Albrecht Nauck, N. Kleine, C. �rskov et al. · Diabetologia
Open access |
Aug 1993 |
1,098 |
| 7 |
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia
Open access |
12 Jan 2015 |
699 |
| 8 |
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
Michael Albrecht Nauck, Gary E. Meininger, D. Sheng et al. · Diabetes Obesity and Metabolism
Open access |
23 Jan 2007 |
669 |
| 9 |
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Carolyn Fiona Deacon, Michael Albrecht Nauck, Maibritt Toft-Nielsen et al. · Diabetes
|
Sep 1995 |
667 |
| 10 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley, Michael Albrecht Nauck, Timothy Silleck Bailey et al. · The Lancet
|
Apr 2010 |
590 |
| 11 |
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse, Michael Albrecht Nauck, Thomas M. Forst et al. · The Lancet
|
6 Nov 2012 |
567 |
| 12 |
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Michael Albrecht Nauck, Stefano Del Prato, Juris Jendrik Meier et al. · Diabetes Care
Open access |
5 Aug 2011 |
535 |
| 13 |
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
B. Willms, Jakob Werner, Jens Juul Holst et al. · The Journal of Clinical Endocrinology & Metabolism
|
1996 |
468 |
| 14 |
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Michael Albrecht Nauck, Irfan Vardarli, Carolyn Fiona Deacon et al. · Diabetologia
Open access |
24 Sep 2010 |
464 |
| 15 |
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
Michael Albrecht Nauck, S. Duran, D. Kim et al. · Diabetologia
Open access |
7 Dec 2006 |
441 |
| 16 |
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Michael Albrecht Nauck, Guido Kemmeries, Jens Juul Holst et al. · Diabetes
Open access |
23 Mar 2011 |
386 |
| 17 |
Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
Juris Jendrik Meier, Baptist Gallwitz, Stefan Salmen et al. · The Journal of Clinical Endocrinology & Metabolism
|
Jun 2003 |
374 |
| 18 |
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
Kirsten Vollmer, Jens Juul Holst, Birgit Baller et al. · Diabetes
Open access |
6 Dec 2007 |
359 |
| 19 |
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael Albrecht Nauck · Drug Design Development and Therapy
Open access |
Sep 2014 |
345 |
| 20 |
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
Juris Jendrik Meier, Michael Albrecht Nauck, Daniel Kranz et al. · Diabetes
|
Mar 2004 |
336 |
| 21 |
Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients
W. Creutzfeldt, N. Kleine, B. Willms et al. · Diabetes Care
|
Jun 1996 |
336 |
| 22 |
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley, Michael Albrecht Nauck, Anthony H Barnett et al. · The Lancet Diabetes & Endocrinology
|
5 Feb 2014 |
327 |
| 23 |
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
Juris Jendrik Meier, Baptist Gallwitz, Nina Siepmann et al. · Diabetologia
Open access |
Jun 2003 |
317 |
| 24 |
Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
JOHAN H. JENDLE, Michael Albrecht Nauck, David Richard Matthews et al. · Diabetes Obesity and Metabolism
Open access |
22 Sep 2009 |
308 |
| 25 |
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
Frauke Fehse, MICHAEL E. TRAUTMANN, Jens Juul Holst et al. · The Journal of Clinical Endocrinology & Metabolism
|
Nov 2005 |
302 |
| 26 |
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Michael Albrecht Nauck · The American Journal of Medicine
|
30 Dec 2010 |
293 |
| 27 |
Glucagon-like peptide 1(GLP-1) in biology and pathology
Juris Jendrik Meier, Michael Albrecht Nauck · Diabetes/Metabolism Research and Reviews
|
Mar 2005 |
288 |
| 28 |
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Michael Albrecht Nauck, Daniel Wollschläger, Jakob Werner et al. · Diabetologia
Open access |
21 Nov 1996 |
288 |
| 29 |
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Spectrum
Open access |
Aug 2012 |
287 |
| 30 |
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Michael Albrecht Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez et al. · Diabetes Care
Open access |
18 Apr 2014 |
285 |
| 31 |
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
Juris Jendrik Meier, Arnica Gethmann, Oliver Götze et al. · Diabetologia
Open access |
30 Jan 2006 |
275 |
| 32 |
Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans
Juris Jendrik Meier, Michael Albrecht Nauck, Andrea Pott et al. · Gastroenterology
Open access |
2006 |
264 |
| 33 |
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg, Soomin Park, Prajakti A. Kothare et al. · Regulatory Peptides
|
17 Jul 2008 |
260 |
| 34 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
Richard E. Pratley, Michael Albrecht Nauck, Timothy Silleck Bailey et al. · International Journal of Clinical Practice
Open access |
Mar 2011 |
253 |
| 35 |
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Steven P. Marso, Neil R Poulter, Steven E. Nissen et al. · American Heart Journal
Open access |
2 Oct 2013 |
251 |
| 36 |
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
Stefano Del Prato, Michael Albrecht Nauck, Santiago Durán-Garcia et al. · Diabetes Obesity and Metabolism
|
4 Mar 2015 |
234 |
| 37 |
Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes
Juris Jendrik Meier, Katrin Hücking, Jens Juul Holst et al. · Diabetes
|
Nov 2001 |
231 |
| 38 |
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael Albrecht Nauck, John R. Petrie, Giorgio Sesti et al. · Diabetes Care
Open access |
10 Sep 2015 |
231 |
| 39 |
Gastric Inhibitory Polypeptide: the neglected incretin revisited
Juris Jendrik Meier, Michael Albrecht Nauck, Wolfgang Ekkehard Schmidt et al. · Regulatory Peptides
|
Jul 2002 |
226 |
| 40 |
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaëla Diamant, Michael Albrecht Nauck, Rimma M. Shaginian et al. · Diabetes Care
|
11 Jul 2014 |
226 |
| 41 |
Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee
Hans Müller-Faßbender, Gerhard L. Bach, Wolfgang Haase et al. · Osteoarthritis and Cartilage
|
Mar 1994 |
216 |
| 42 |
Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Juris Jendrik Meier, Michael Albrecht Nauck · Diabetes
Open access |
28 Apr 2010 |
214 |
| 43 |
Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels
W. Creutzfeldt, Reinhold Ebert, B. Willms et al. · Diabetologia
Open access |
1978 |
214 |
| 44 |
Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses
Tanya J. Little, Amelia N. Pilichiewicz, Antonietta Russo et al. · The Journal of Clinical Endocrinology & Metabolism
|
21 Feb 2006 |
212 |
| 45 |
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Michael Albrecht Nauck, Birgit Baller, Juris Jendrik Meier · Diabetes
|
Dec 2004 |
209 |
| 46 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
Thomas L. Seck, Michael Albrecht Nauck, D. Sheng et al. · International Journal of Clinical Practice
Open access |
4 Mar 2010 |
209 |
| 47 |
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Michael Albrecht Nauck · Diabetes Care
Open access |
4 May 2013 |
205 |
| 48 |
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
Michael Albrecht Nauck, Graham C. Ellis, Penny R. Fleck et al. · International Journal of Clinical Practice
Open access |
15 Dec 2008 |
205 |
| 49 |
GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
Nikolaos Mentis, Irfan Vardarli, L. Köthe et al. · Diabetes
Open access |
17 Feb 2011 |
197 |
| 50 |
Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
Mahesh Michael Umapathysivam, Michael Y. Lee, Karen L. Jones et al. · Diabetes
Open access |
2 Oct 2013 |
193 |